Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Agnosia × Midazolam × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 16 Breast Neoplasms 10 Carcinoma, Non-Small-Cell Lung 9 Lung Neoplasms 5 Prostatic Neoplasms 4 Melanoma 4 Solid Tumor 3 Neoplasm Metastasis 3 Lymphoma, Non-Hodgkin 3 Leukemia, Myeloid, Acute 3 Recurrence 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Lymphoma 2 Glioma 2 Gastrointestinal Stromal Tumors 2 Colorectal Neoplasms 2 Colonic Neoplasms 2 Choledochal Cyst 2 Carcinoma 2 Anxiety Disorders 2 Advanced Solid Tumor 2 Advanced Malignancies 2 cMET-dysregulated Advanced Solid Tumors 1 Urothelial Cancer 1 Urinary Bladder Neoplasms 1 Thyroid Neoplasms 1 Terminal Cancer 1 Synovitis, Pigmented Villonodular 1 Solid Tumours 1 Solid Tumour 1

Interventions

Bupivacaine 9 Ketamine 8 Dexmedetomidine 7 Analgesics, Opioid 7 Ropivacaine 6 Fentanyl 6 Anesthesia, General 6 Acetaminophen 6 Morphine 5 Lidocaine 5 Acupuncture Therapy 5 Surveys and Questionnaires 4 Pregabalin 4 Ethanol 4 Anesthesia, Local 4 parecoxib 3 Tramadol 3 Sodium Chloride 3 Saline Solution 3 Propofol 3 Ketorolac 3 Control Groups 3 Anesthetics, Local 3 Analgesia, Epidural 3 trimebutine 3-thiocarbamoylbenzenesulfonate 2 Transcutaneous Electric Nerve Stimulation 2 Tea 2 Radiofrequency Ablation 2 Oxycodone 2 Magnesium Sulfate 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04597268 2023-01-10

Dexmedetomidine Versus Ketamine Versus Midazolam in Endoscopic Procedures

National Cancer Institute, Egypt

Phase NA Completed

Agnosia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡